Next Article in Journal / Special Issue
In Vivo Evaluation of a New Recombinant Hyaluronidase to Improve Gene Electro-Transfer Protocols for DNA-Based Drug Delivery against Cancer
Previous Article in Journal
Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis
Previous Article in Special Issue
Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
Review

Oncolytic Viruses for Canine Cancer Treatment

1
Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 14080, Mexico
2
Department of Hematology, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
*
Author to whom correspondence should be addressed.
Received: 19 September 2018 / Revised: 16 October 2018 / Accepted: 23 October 2018 / Published: 27 October 2018
(This article belongs to the Special Issue Cancer Vaccines: Research and Applications)
Oncolytic virotherapy has been investigated for several decades and is emerging as a plausible biological therapy with several ongoing clinical trials and two viruses are now approved for cancer treatment in humans. The direct cytotoxicity and immune-stimulatory effects make oncolytic viruses an interesting strategy for cancer treatment. In this review, we summarize the results of in vitro and in vivo published studies of oncolytic viruses in different phases of evaluation in dogs, using PubMed and Google scholar as search platforms, without time restrictions (to date). Natural and genetically modified oncolytic viruses were evaluated with some encouraging results. The most studied viruses to date are the reovirus, myxoma virus, and vaccinia, tested mostly in solid tumors such as osteosarcomas, mammary gland tumors, soft tissue sarcomas, and mastocytomas. Although the results are promising, there are issues that need addressing such as ensuring tumor specificity, developing optimal dosing, circumventing preexisting antibodies from previous exposure or the development of antibodies during treatment, and assuring a reasonable safety profile, all of which are required in order to make this approach a successful therapy in dogs. View Full-Text
Keywords: oncolytic virus; canine cancer; immunotherapy; canine treatment oncolytic virus; canine cancer; immunotherapy; canine treatment
Show Figures

Figure 1

MDPI and ACS Style

Sánchez, D.; Cesarman-Maus, G.; Amador-Molina, A.; Lizano, M. Oncolytic Viruses for Canine Cancer Treatment. Cancers 2018, 10, 404. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10110404

AMA Style

Sánchez D, Cesarman-Maus G, Amador-Molina A, Lizano M. Oncolytic Viruses for Canine Cancer Treatment. Cancers. 2018; 10(11):404. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10110404

Chicago/Turabian Style

Sánchez, Diana, Gabriela Cesarman-Maus, Alfredo Amador-Molina, and Marcela Lizano. 2018. "Oncolytic Viruses for Canine Cancer Treatment" Cancers 10, no. 11: 404. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers10110404

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop